CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project develops oncolytic adenoviruses that produce trastuzumab, a treatment for Her2+ cancers, directly within tumors. By modifying the virus for targeted delivery, it aims to enhance anti-tumor effects while reducing side effects compared to traditional intravenous methods.
Metastatic breast, ovarian, gastric and esophageal cancer are currently incurable and therefore require new and innovative treatment approaches.
The objective of this project is to construct oncolytic adenoviruses that code for trastuzumab (HerceptinR), a monoclonal antibody against tumor associated receptor Her2.
Intravenous trastuzumab is already widely used for treatment of Her2+ breast cancer, and is being actively studied for other tumor types that frequently feature Her2 amplification, inc…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
